Latest Articles
Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer - Yahoo Finance
Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer Yahoo Finance
Published: April 23, 2026, 8:06 p.m.
International Experts Convene in Tenerife to Discuss Advances in Gynaecological Cancer - Tenerife Weekly News
International Experts Convene in Tenerife to Discuss Advances in Gynaecological Cancer Tenerife Weekly News
Published: April 23, 2026, 10:33 a.m.
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer - BioSpace
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer BioSpace
Published: April 23, 2026, 6:25 a.m.
Utepreva launches FDA-cleared endometrial sampler to support endometrial cancer detection - Contemporary OB/GYN
Utepreva launches FDA-cleared endometrial sampler to support endometrial cancer detection Contemporary OB/GYN
Published: April 22, 2026, 9:05 p.m.
Mo-Rez shows strong early responses in ovarian, endometrial cancers - Rare Cancer News
Mo-Rez shows strong early responses in ovarian, endometrial cancers Rare Cancer News
Published: April 22, 2026, 4:40 p.m.
Mo-Rez shows strong early responses in gynecologic cancers - Rare Cancer News
Mo-Rez shows strong early responses in gynecologic cancers Rare Cancer News
Published: April 22, 2026, 2:43 p.m.
Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort - Via Medica Journals
Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort Via Medica Journals
Published: April 22, 2026, 2:34 p.m.
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer - PR Newswire
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer PR Newswire
Published: April 22, 2026, 2:08 p.m.
BioNTech (BNTX) Is Up 13.4% After Positive HER2 Endometrial Cancer Phase 2 Data Release - simplywall.st
BioNTech (BNTX) Is Up 13.4% After Positive HER2 Endometrial Cancer Phase 2 Data Release simplywall.st
Published: April 22, 2026, 11:30 a.m.
S’pore-led studies make breakthroughs in treating cancers in women - The Straits Times
S’pore-led studies make breakthroughs in treating cancers in women The Straits Times
Published: April 21, 2026, 1:22 p.m.
Link copied to clipboard!